Dimerix enters deal with FUSO for DMX-200 Japan

Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited (ASX: DXB) have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan.

It is the third licensing deal Dimerix has secured for DMX-200. The company has a deal with Advanz Pharma covering the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand for commercialization of DMX-200 for the treatment of FSGS following regulatory approval. The company also has a licensing deal with Taiba in May 2024 incorporating several Middle Eastern countries.

Dimerix, whose shares leapt 35% to A$0.48 on the news today, retains all rights to commercialize DMX-200 in all territories other than those covered by the FUSO, Advanz Pharma and Taiba license agreements. DMX-200 is currently in global Phase III clinical development, with a blinded interim analysis anticipated in August 2025.